This valuable study reports on a novel role of PD-1 in early T cell differentiation, showing that PD-1 stimulation impairs Th2 differentiation more effectively than that of Th1, with implications for ...
HER2-negative gastric cancer is not favorable in patients who have PD-L1-negative tumors, as measured by a combined positive score (CPS) or tumor area positivity (TAP) score below 1. One ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 expression less than 1. In an 11 to 1 vote, the FDA’s Oncologic Drug Advisory ...
After picking apart PD-L1 subgroup data from separate phase 3 trials of BMS’ Opdivo, Merck’s Keytruda and BeiGene’s Tevimbra, the FDA found that the drugs’ benefit-risk profiles ...
The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in first-line advanced gastric cancer with PD-L1 expression less than 1. In a 2 to 10 vote, the FDA’s ...
NEW YORK – The US Food and Drug Administration will ask experts in its Oncologic Drugs Advisory Committee (ODAC) on Thursday whether it should narrow two currently approved indications of checkpoint ...
Introduction: Programmed death ligand – 1 (PD-L1) expression is a well-established predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). Programmed death – 1 (PD-1) serves as ...
The following antibodies were used to stain cells: Anti-Human CD138 (MI15, 552026), Anti-Human CD47 (B6H12, #556046), Anti-Human PD-L1 (MIH1, #557924), Anti-Human CD3 (SK7, #557832), were all ...